Could CRISPR Cure HIV? US Biotech Excision Raises $60M to Find Out
Excision BioTherapeutics has secured $60 million to advance its CRISPR-based therapy, EBT-101, into clinical trials, aiming to cure HIV by excising the viral DNA from human cells. This innovative approach could potentially eliminate the need for lifelong medication and prevent the progression to AIDS.
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
• Vera Therapeutics has appointed Jason S. Carter as Chief Legal Officer, effective immediately, to support the company's next phase.
• Carter brings over 20 years of experience in legal counsel to life sciences, biotechnology, and pharmaceutical companies, including Kite Pharma and Novartis.
• Vera anticipates topline results from the ORIGIN 3 trial of atacicept in IgAN in Q2 2025, with a planned BLA submission to the FDA later in the year.
• Carter will support the advancement of atacicept as a potential treatment for IgAN and other autoimmune kidney diseases, leveraging his expertise in regulatory approvals and IP management.
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
• Vera Therapeutics has appointed Jason S. Carter as Chief Legal Officer, effective immediately, to support the company's next phase.
• Carter brings over 20 years of experience in legal counsel to life sciences, biotechnology, and pharmaceutical companies, including Kite Pharma and Novartis.
• Vera anticipates topline results from the ORIGIN 3 trial of atacicept in IgAN in Q2 2025, with planned BLA submission to the FDA later in the year.
• Carter expressed enthusiasm to support the advancement of atacicept as a potential treatment for IgAN and other autoimmune kidney diseases.
CHEST 2024: Major Breakthroughs in COPD Treatment and Pulmonary Embolism Management Unveiled
• The CHEST 2024 annual meeting gathered 6,000-8,000 pulmonology experts, highlighting significant advances in Pulmonary Embolism Response Teams (PERT) and personalized treatment approaches.
• Groundbreaking developments in COPD treatment were presented, moving beyond traditional inhaler therapies to include biologics and precision medicine based on patient phenotypes and genotypes.
• The conference addressed critical issues in pulmonary care, including sleep medicine advancements, racial disparities in treatment outcomes, and the importance of tailored patient care across various respiratory conditions.
Adaptimmune's Tecelra: First-of-its-Kind Cancer Therapy for Synovial Sarcoma
• Adaptimmune's Tecelra, a novel therapy for synovial sarcoma, has received FDA approval and is poised to deliver its first patient orders, marking a significant advancement in cancer treatment.
• Tecelra is the first therapy that modifies a patient’s own immune cells to target a solid tumor, offering new hope for treating this rare cancer.
• Gemma Biotherapeutics is set to receive up to $100 million from Brazil’s health ministry to develop gene therapies for rare central nervous system disorders.
• Pennsylvania is experiencing a surge in whooping cough cases, leading to increased masking requirements in some healthcare facilities like CHOP.
Sling Therapeutics Launches with $35M Series A Financing to Develop Oral Small Molecule for Thyroid Eye Disease
Sling Therapeutics, Inc. has officially launched with a $35M Series A financing led by TPG's The Rise Fund, aiming to develop linsitinib, an oral small molecule for treating Thyroid Eye Disease (TED). The company has received FDA IND clearance and is preparing to initiate a Phase 2b clinical trial. Linsitinib, designed to inhibit the IGF-1R signaling pathway, offers a potential convenient oral treatment option for TED patients, aiming to reduce the treatment burden significantly.
© Copyright 2025. All Rights Reserved by MedPath